Tag: SARS-CoV-2

Finding effective and safe vaccines is crucial in the fight against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19). As a vital component of a subunit vaccine, the adjuvant strengthens the antigen-induced immune responses. Researchers at the National Center for Nanoscience and Technology of China, the

Analysis indicated the number of mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) doubles every 72 days. As the coronavirus disease 2019 (COVID-19) pandemic continues infecting more people, SARS-CoV-2 is also evolving. Several new variants of the virus have now been discovered, some more infectious than the original strains. This

A team of scientists from Brazil recently explored the abilities of the UK, South African, and Brazilian variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evade host CD8+ T cell responses induced by natural infection or vaccination. The findings reveal reduced antigenic coverage for the P.2 Brazilian lineage, indicating its ability to evade

The vast majority of people infected with SARS-CoV-2 clear the virus, but those with compromised immunity—such as individuals receiving immune-suppressive drugs for autoimmune diseases—can become chronically infected. As a result, their weakened immune defenses continue to attack the virus without being able to eradicate it fully. This physiological tug-of-war between human host and pathogen offers

SARS-CoV-2, the virus that causes COVID-19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread or evade the immune system. Such variants have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Understanding how well the COVID-19 vaccines

As new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, fueling the continued spread of the coronavirus disease 2019 (COVID-19) pandemic, a new study offers encouragement. Released as a preprint on the bioRxiv* server, the study reports the protection offered by antibodies elicited by natural infection against the newer variants

(HealthDay)—The T-Detect COVID Test, a T cell-based test that helps to identify individuals with recent or prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, was granted emergency use authorization, the U.S. Food and Drug Administration announced Friday. The next-generation sequencing-based test analyzes DNA sequences to identify those with an adaptive T cell immune response

An interesting new study by researchers in Australia, which has been published in the journal PLOS ONE, suggests that lifestyle changes due to pandemic restrictions on outdoor mobility have been small. But they warn that these may accumulate over time. The coronavirus disease 2019 (COVID-19) pandemic, caused by the rapid and extensive spread of the

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or

With several vaccines already having received Emergency Use Authorization (EUA) against coronavirus disease 2019 (COVID-19), vaccination campaigns have already begun in several countries the world over. However, as with the disease itself, the remedy continues to be plagued by issues of inequity and disparity. A new preprint examines the racial and ethnic differences between COVID-19

The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally, infecting over 114 million people. The virus first emerged in late December 2019 in Wuhan, China, from a potential animal host. Zoonotic diseases have caused outbreaks throughout history, claiming millions of lives. These diseases occur when pathogens

New data from Addenbrooke’s Hospital in Cambridge suggests that a single dose of the Pfizer BioNTech vaccine can reduce by four-fold the number of asymptomatic SARS-CoV-2 infections. This implies that the vaccine could significantly reduce the risk of transmission of the virus from people who are asymptomatic, as well as protecting others from getting ill.

New data from Addenbrooke's Hospital in Cambridge suggests that a single dose of the Pfizer BioNTech vaccine can reduce by four-fold the number of asymptomatic SARS-CoV-2 infections. This implies that the vaccine could significantly reduce the risk of transmission of the virus from people who are asymptomatic, as well as protecting others from getting ill.

A safe, fast and cheap testing method that uses magnetic nanoparticles to detect viruses in both clinical and wastewater samples has been developed by KAUST researchers. The centrifuge-free approach is compatible with magnetic bead-based automated systems that are already used to process hundreds of samples. Our silica magnetic nanoparticle-based workflow can be assembled from scratch

The coronavirus disease 2019 (COVID-19) pandemic has claimed well over 2.4 million lives, but its long-term sequelae are still being identified. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces an infection that may be associated with a wide spectrum of disease, from asymptomatic to critical or terminal respiratory failure or multi-organ dysfunction. A new

Several genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have risen to prominence during the course of the coronavirus disease 2019 (COVID-19) pandemic, one of which is the UK variant – termed B.1.1.7 by the Centers for Disease Control and Prevention (CDC). This variant is associated with increased transmissibility compared to the wild-type

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc across the globe. Scientists are racing to develop effective therapeutic regimens to combat the infection. One of therapy currently used to stimulate a robust immune response against the virus is monoclonal antibodies, a treatment used for

The coronavirus disease 2019 (COVID-19) pandemic – caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is still causing hundreds of thousands of new cases globally. Therapeutic antibodies have been used to attempt to counter and contain the virus. Convalescent plasma (CP) obtained from recovered COVID-19 patients is also in use in many

The coronavirus disease 2019 (COVID-19) is a transmissible viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the ongoing global pandemic. The virus was first detected in Wuhan, China, at the end of 2019 and to date has caused over 109 million infections worldwide. With over 2.4 million

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School of Medicine report that individual